








FIG. 1


NQO1-ARE Luciferase Activity**(a)****GSTA2-ARE Luciferase Activity****(b)****FIGS. 2a & b**




(a)



(b)







(c)




(d)

FIGS. 3a – d



FIGS. 4a – d



FIGS. 5a & b




FIG. 6




FIG. 7






FIG. 8




(a)




(b)

FIGS. 9a & b



(c)



(d)

FIGS. 9c & d




FIG. 10






FIG. 11




(a)




(b)

FIGS. 12a & b



(c)



(d)

FIGS. 12c & d




FIG. 13







FIG. 14



FIGS. 15a & b




(a)



(b)

FIGS. 16a & b



FIGS. 17a & b





FIG. 18



FIGS. 19a – e






FIG. 20

Systemic LPS: Body Weight: 63415



(a)


Systemic LPS: Body Weight: RTA 405



(b)


FIGS. 21a & b

Systemic LPS: % Survival: 63415



(c)

Systemic LPS: % Survival: RTA 405



(d)

FIGS. 21c & d




FIG. 22








FIG. 23



FIGS. 24a & b




(a)




(b)

FIGS. 25a & b




(a)




(b)

FIGS. 26a & b




(a)




(b)

FIGS. 27a & b




(a)





(b)

FIGS. 28a & b




(a)






(a)




(b)

FIGS. 30a & b



(a)



(b)

FIGS. 31a & b




FIG. 32





FIG. 33



FIGS. 34a & b

Effect of RTA 408 on the Incidence of Grade 3 Dermatitis




FIG. 35




FIG. 36




FIG. 37

**Effect of RTA 408 on the Incidence of Grade 3
Dermatitis up to Day 28**




FIG. 38




FIG 39a




FIG 39b




FIG. 40




FIG 41




FIG. 42





FIG. 43






FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51






FIG. 52




PXRD Pattern of RTA 408 Form A

FIG. 53




DSC of RTA 408 Form A

FIG. 54




TGA-MS of RTA 408 Form A

FIG. 55




PXRD Pattern of RTA 408 Form B

FIG. 56



DSC of RTA 408 Form A

FIG. 57



TGA-MS of RTA 408 Form B

FIG. 58